Carlo Rizzuto
QuietNamed in filings at Versant Venture Capital
- Board seats filed
- 10
- Named on a board
- 0
all filings on record
Named in filings at Versant Venture Capital
all filings on record
last 24 months
from a verified or cited source
| Pep2Tango Therapeutics | Biotech & pharma | September 2024 | Versant Vantage |
| Nexo Therapeutics | Biotech & pharma | November 2022 | Versant Vantage |
| Jnana Therapeutics | Biotech & pharma | August 2021 | Polaris Partners, Versant Vantage |
| Graphite Bio | Biotech & pharma | March 2021 | Versant Vantage |
| Century Therapeutics | Biotech & pharma | February 2021 | Versant Vantage |
| Pandion Therapeutics Holdco | Biotech & pharma | March 2020 | Versant Vantage |
| 858 Therapeutics | Biotech & pharma | March 2020 | Versant Vantage |
| Quentis Therapeutics | Biotech & pharma | February 2018 | Polaris Partners, Versant Vantage |
| Pandion Therapeutics | Biotech & pharma | January 2018 | Versant Vantage |
| VenatoRx Pharmaceuticals | Biotech & pharma | July 2017 | Versant Vantage |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name Carlo Rizzuto on the board, based on 10 filed seats with a verified or cited source.